CDMO industry leaders on resilience, capability gaps, and the partnerships that will define the next decade
CDMO industry leaders convened at CDMO Live Europe 2026 to confront a sector in reset, where geopolitical pressures are replacing lowest-cost sourcing with regional resilience, where capacity is abundant yet capability remains scarce, and where the sequential hand-off model of outsourcing is no longer fit for purpose. The conversations surfaced a clear consensus: differentiation will belong to partners that integrate accountability across drug substance and drug product, embed AI into validated processes rather than chasing hype, and measure value through total cost of ownership rather than price per batch.
Read the full report to understand the structural shifts that will define the next decade of pharma outsourcing.
CDMO industry leaders convened at CDMO Live Europe 2026 to confront a sector in reset, where geopolitical pressures are replacing lowest-cost sourcing with regional resilience, where capacity is abundant yet capability remains scarce, and where the sequential hand-off model of outsourcing is no longer fit for purpose. The conversations surfaced a clear consensus: differentiation will belong to partners that integrate accountability across drug substance and drug product, embed AI into validated processes rather than chasing hype, and measure value through total cost of ownership rather than price per batch.
Read the full report to understand the structural shifts that will define the next decade of pharma outsourcing.
Share article
Related Content